Ignite Creation Date:
2024-05-05 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00317486
Status:
COMPLETED
Last Update Posted:
2010-02-15
First Post:
2006-04-21
Brief Title:
Effects of Tracleer Bosentan on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
A Multi-center Randomized Double-blind Placebo-controlled Study to Evaluate the Effects of Tracleer Bosentan on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the effects of bosentan on oxygen saturation hemodynamics and exercise capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology Patients receive bosentan or placebo for 16 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None